Merck (MRK) Long-Term Investments (2009 - 2026)

Merck (MRK) has reported Long-Term Investments for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 343.78% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 343.78% YoY), while the FY2025 annual figure was $956.0 million, up 106.48% from the prior year.
• Long-Term Investments rose to $1.1 billion in Q1 2026 per MRK's latest filing, from $956.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.3 billion in Q3 2023 and bottomed at $238.0 million in Q2 2022.
• Historically, Long-Term Investments has averaged $635.0 million across 5 years, with a median of $622.0 million in 2023.
• Annual changes were most pronounced in 2023 — Long-Term Investments plunged 75.17% — and 2026, when it jumped 343.78%.
• Merck's Long-Term Investments stood at $1.0 billion in 2022, then slumped by 75.17% to $252.0 million in 2023, then surged by 83.73% to $463.0 million in 2024, then jumped by 106.48% to $956.0 million in 2025, then climbed by 15.59% to $1.1 billion in 2026.
• Business Quant data shows MRK's Long-Term Investments at $1.1 billion in Q1 2026, $956.0 million in Q4 2025, and $1.1 billion in Q3 2025.